Pharmacokinetics and dosage adjustment in patients with renal dysfunction.
about
Acupuncture and related interventions for the symptoms of chronic kidney diseaseAcupuncture and related interventions for symptoms of chronic kidney diseasePharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal ImpairmentDirect Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and SimilaritiesA Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKDDevelopment of an adverse drug reaction risk assessment score among hospitalized patients with chronic kidney diseaseA survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directionsPharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment.Anticoagulation Therapy in Patients with Chronic Kidney Disease.Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review.Adverse outcomes of anticoagulant use among hospitalized patients with chronic kidney disease: a comparison of the rates of major bleeding events between unfractionated heparin and enoxaparinFullerenol cytotoxicity in kidney cells is associated with cytoskeleton disruption, autophagic vacuole accumulation, and mitochondrial dysfunctionThe influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.Ceftriaxone-induced acute encephalopathy in a peritoneal dialysis patient.Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models.Dose selection method for pharmacokinetic study in hemodialysis patients using a subpharmacological dose: oseltamivir as a model drug.Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?Determination of vancomycin and gentamicin clearance in an in vitro, closed loop dialysis system.Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.Comparative pharmacokinetics of catalpol and acteoside in normal and chronic kidney disease rats after oral administration of Rehmannia glutinosa extract.Drug-induced cerebral glucose metabolism resembling Alzheimer's Disease: a case study.Patient safety issues in CKD: core curriculum 2015.Pattern and Predictors of Medication Dosing Errors in Chronic Kidney Disease Patients in Pakistan: A Single Center Retrospective AnalysisClinical Pharmacology Studies in Critically Ill Children.Drug dosage adjustment in hospitalized patients with renal impairment at Tikur Anbessa specialized hospital, Addis Ababa, EthiopiaPopulation pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infectionAssessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomersPharmacokinetic profile of defibrotide in patients with renal impairment.Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function.Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties.Management of hematological malignancies in patients affected by renal failure.Renal profiles of anticoagulants.The use of newer antiepileptic drugs in patients with renal failure.Malaria prophylaxis in patients with renal impairment: a review.Prediction of drug disposition on the basis of its chemical structure.A review of the pharmacokinetic implications of schistosomiasis.Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.
P2860
Q24235782-F2C1A71B-D21A-409A-8520-76C8C96830E5Q26471416-3749D6BA-111A-4F77-BAC9-A75F28794615Q26751452-333FB259-7121-489F-BF90-E33745230DBAQ26787046-15259BC1-3E07-4929-8073-8AC944413723Q28087621-E066D6AD-F5AF-46B6-A7C5-B5E6EC70A528Q28538142-9839221A-2368-443A-B236-1A83AF77E227Q30491777-2C5CE7BD-86D2-48A7-BEBC-EA9AE0388A8CQ30614811-4688FE22-7C16-4A41-83FA-0A196B741C0EQ33435357-CEC49E4F-C489-484E-B159-DEA2C14FB81CQ33654022-A19731DD-8181-40DD-8529-E7B9F4D09505Q33967473-9B885C4E-6A18-40C4-BB0E-9BEEFB7A8CAEQ34122392-121CCE14-17C4-4E82-921B-A88CF7C3533CQ34172581-100A246B-E79B-411D-A13D-ABF672A6CC70Q34315521-964A725E-4C1F-49A3-9EE2-509EF8B55291Q34754405-55D96426-FD66-4569-AD8C-A5EF42427D35Q35099010-09D859EA-A0B1-4089-A341-7C986100238EQ35122440-039D3285-93DD-4AAD-81A0-844F952A06E3Q35219662-25CA9A9A-BD0C-4D48-8B58-3623F93CF21EQ35531011-8C03A666-0E61-49C5-8D0E-26DCA88FBB74Q35557435-AA933336-3381-425E-A3DC-EEFAFBD84CDFQ35648605-8F1866BF-CB11-4BBA-B44B-4A5F0895F04FQ35688580-1B25A877-F399-4A3B-8460-D58C0E45CAD0Q35798287-7AED9155-4C70-4CC2-8927-CE551BB15266Q36066029-FA11E49C-5423-4958-BC4E-AA1F1197DE74Q36120465-B8FBFC1B-1FF8-4DF9-94BB-1548D976E08FQ36135591-B9E7EA49-A997-4CED-BB6B-57F386A3D370Q36558341-D31DE54F-02E8-450B-B00A-1AD047AF4F3EQ36881704-00215931-EB65-45C8-95D9-DE0B52D71D0FQ37030741-5923B17A-8EEF-4D2E-9CC0-5E6A23FB4F0AQ37194132-AA57A27E-FCB8-4BE4-B197-71701367E4D0Q37679896-E46B5FC7-7B7B-47ED-BD15-9D17C74B3207Q37740151-ABD738DA-2C3D-4067-B564-9F43A55C1F77Q37761376-C7211885-96C7-46E2-9441-9DBBB058FF3CQ37854710-F5C7CAE1-AA0C-4D83-BBE1-4A765298ED7BQ37879330-C18B3F84-0348-4078-835E-2199D7FAE4BBQ37965704-E2F035D1-BC4E-4AF1-8064-6738EACE987AQ38078263-18D6A8E7-60AD-4904-AC52-6C466442533CQ38086778-33BA05FD-BDC2-47C3-BF79-ECB10114B309Q38088213-8E9565CE-42B9-47DE-B5F1-4005D49FCA33Q38152329-D1EFE33B-8874-4AAE-A7F1-7EDE560D61C3
P2860
Pharmacokinetics and dosage adjustment in patients with renal dysfunction.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics and dosage adjustment in patients with renal dysfunction.
@en
Pharmacokinetics and dosage adjustment in patients with renal dysfunction.
@nl
type
label
Pharmacokinetics and dosage adjustment in patients with renal dysfunction.
@en
Pharmacokinetics and dosage adjustment in patients with renal dysfunction.
@nl
prefLabel
Pharmacokinetics and dosage adjustment in patients with renal dysfunction.
@en
Pharmacokinetics and dosage adjustment in patients with renal dysfunction.
@nl
P2860
P1476
Pharmacokinetics and dosage adjustment in patients with renal dysfunction
@en
P2093
Roger K Verbeeck
P2860
P2888
P304
P356
10.1007/S00228-009-0678-8
P577
2009-06-20T00:00:00Z